Imexpharm Statistics

Total Valuation

Imexpharm has a market cap or net worth of VND 8.04 trillion. The enterprise value is 7.97 trillion.

Market Cap	8.04T
Enterprise Value	7.97T

Important Dates

The next estimated earnings date is Friday, July 18, 2025.

Earnings Date	Jul 18, 2025
Ex-Dividend Date	Jun 9, 2025

Share Statistics

Imexpharm has 154.01 million shares outstanding. The number of shares has decreased by -1.93% in one year.

Current Share Class	154.01M
Shares Outstanding	154.01M
Shares Change (YoY)	-1.93%
Shares Change (QoQ)	-7.30%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	0.26%
Float	n/a

Valuation Ratios

The trailing PE ratio is 26.00.

PE Ratio	26.00
Forward PE	n/a
PS Ratio	3.48
PB Ratio	3.58
P/TBV Ratio	3.70
P/FCF Ratio	n/a
P/OCF Ratio	80.05
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 14.86, with an EV/FCF ratio of -5,618.24.

EV / Earnings	25.79
EV / Sales	3.45
EV / EBITDA	14.86
EV / EBIT	18.43
EV / FCF	-5,618.24

Financial Position

The company has a current ratio of 4.48, with a Debt / Equity ratio of 0.17.

Current Ratio	4.48
Quick Ratio	2.11
Debt / Equity	0.17
Debt / EBITDA	0.73
Debt / FCF	-274.10
Interest Coverage	81.35

Financial Efficiency

Return on equity (ROE) is 15.18% and return on invested capital (ROIC) is 11.03%.

Return on Equity (ROE)	15.18%
Return on Assets (ROA)	10.04%
Return on Invested Capital (ROIC)	11.03%
Return on Capital Employed (ROCE)	17.27%
Revenue Per Employee	1.60B
Profits Per Employee	213.81M
Employee Count	1,452
Asset Turnover	0.86
Inventory Turnover	1.78

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +67.25% in the last 52 weeks. The beta is 0.75, so Imexpharm's price volatility has been lower than the market average.

Beta (5Y)	0.75
52-Week Price Change	+67.25%
50-Day Moving Average	46,557.00
200-Day Moving Average	46,446.75
Relative Strength Index (RSI)	60.45
Average Volume (20 Days)	314,976

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Imexpharm had revenue of VND 2.31 trillion and earned 309.16 billion in profits. Earnings per share was 2,007.45.

Revenue	2.31T
Gross Profit	1.09T
Operating Income	432.60B
Pretax Income	421.71B
Net Income	309.16B
EBITDA	536.47B
EBIT	432.60B
Earnings Per Share (EPS)	2,007.45

Full Income Statement

Balance Sheet

The company has 455.35 billion in cash and 388.98 billion in debt, giving a net cash position of 66.38 billion or 430.98 per share.

Cash & Cash Equivalents	455.35B
Total Debt	388.98B
Net Cash	66.38B
Net Cash Per Share	430.98
Equity (Book Value)	2.25T
Book Value Per Share	14,593.83
Working Capital	1.43T

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 100.43 billion and capital expenditures -101.85 billion, giving a free cash flow of -1.42 billion.

Operating Cash Flow	100.43B
Capital Expenditures	-101.85B
Free Cash Flow	-1.42B
FCF Per Share	-9.21

Full Cash Flow Statement

Margins

Gross margin is 47.25%, with operating and profit margins of 18.74% and 14.45%.

Gross Margin	47.25%
Operating Margin	18.74%
Pretax Margin	18.27%
Profit Margin	14.45%
EBITDA Margin	23.24%
EBIT Margin	18.74%
FCF Margin	n/a

Dividends & Yields

This stock pays an annual dividend of 500.00, which amounts to a dividend yield of 0.96%.

Dividend Per Share	500.00
Dividend Yield	0.96%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	21.00%
Buyback Yield	1.93%
Shareholder Yield	2.89%
Earnings Yield	3.85%
FCF Yield	-0.02%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 17, 2024. It was a forward split with a ratio of 2.

Last Split Date	Sep 17, 2024
Split Type	Forward
Split Ratio	2

Scores

Imexpharm has an Altman Z-Score of 7.91.

Altman Z-Score	7.91
Piotroski F-Score	n/a